News | May 01, 2025
Briefs: Alembic Pharmaceuticals and Bafna Pharmaceuticals
Alembic Pharmaceuticals commissions new facility at Pithampur
Alembic Pharmaceuticals commissions new facility at Pithampur
Delivers robust earnings performance, successfully navigating a dynamic environment
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Distribution agreement enables FUJIFILM India to offer Spectra Logic advanced tape libraries and software solutions to enterprise customers and channel partners
Bayer expects 2025 to be the most difficult year of its turnaround
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The implementation, spearheaded by Deloitte Consulting, brings together domain expertise and cutting-edge technology
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
